Binimetinib (MEK162, ARRY-162) is an orally active, potent, ATP-uncompetitive MEK1/2 inhibitor (IC50 = 12 nM) that inhibits multiple human tumor growth in xenograft mice in vivo regardless of Kras or Braf mutation (30 or 100 mg/kg/day, 100 mg/kg b.i.d.).
Orally active, potent, ATP-uncompetitive MEK1/2 inhibitor that inhibits multiple human tumor growth in vivo regardless of Kras or Braf mutation.
Breast ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal carcinoma (IDC). It is still unclear which DCIS will become invasive and which will remain indolent. Patients often receive surgery and radiotherapy, but this early intervention has
Questions
Reviews
★★★★★ No rating value
Active Filters
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
